GOLIMUMAB, A NEW HUMAN TNF-alpha ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY
Author(s):
Braun, J.; Heijde, A.D. van der; Deodhar, L.; Diekman, J.; Sieper, S.I.; Kim, A.; Beutler, M.; Mack, S.; Xu, J.; Zrubek, B.; Hsu, R.; Inman, O.; GO-RAISE
